Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Ophthalmology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
ASH 2024 Annual Meeting 2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on adolescent vaping

LIVE: Wednesday 29th January, 18:00-19:30 CET

Growing numbers of young people are using e-cigarettes, despite warnings of respiratory effects and addiction. How can doctors tackle the epidemic, and what health effects should you prepare to manage in your clinics?
ADVANCED SEARCH
Log in
Top
BMC Medicine
Published in:

Open Access 18-12-2024 | Type 2 Diabetes | Review

The double life of glucose metabolism: brain health, glycemic homeostasis, and your patients with type 2 diabetes

Authors: Stanley S. Schwartz, Mary E. Herman, May Thet Hmu Tun, Eugenio Barone, D. Allan Butterfield

Published in: BMC Medicine | Issue 1/2024

Login to get access

Abstract

The maintenance of cognitive function is essential for quality of life and health outcomes in later years. Cognitive impairment, however, remains an undervalued long-term complication of type 2 diabetes by patients and providers alike. The burden of sustained hyperglycemia includes not only cognitive deficits but also the onset and progression of dementia-related conditions, including Alzheimer’s disease (AD). Recent research has shown that the brain maintains an independent glucose “microsystem”—evolved to ensure the availability of fuel for brain neurons without interruption by transient hypoglycemia. When this milieu is perturbed, brain hyperglycemia, brain glucotoxicity, and brain insulin resistance can ensue and interfere with insulin signaling, a key pathway to cognitive function and neuronal integrity. This newly understood brain homeostatic system operates semi-autonomously from the systemic glucoregulatory apparatus. Large-scale clinical studies have shown that systemic dysglycemia is also strongly associated with poorer cognitive outcomes, which can be mitigated through appropriate clinical management of plasma glucose levels. Moreover, these studies demonstrated that glucose-lowering agents are not equally effective at preventing cognitive dysfunction. Glucagon-like peptide-1 (GLP-1) receptor analogs and sodium glucose cotransporter 2 inhibitors (SGLT2is) appear to afford the greatest protection; metformin and dipeptidyl peptidase 4 inhibitors (DPP-4is) also significantly improved cognitive outcomes. Sulfonylureas (SUs) and exogenous insulin, on the other hand, do not provide the same protection and may actually worsen cognitive outcomes. In the creation of a treatment plan, comorbid cognitive conditions should be considered. These efficacious treatments create a new gold standard of managing hyperglycemia—one which is consistent with the “complication-centric prescribing” mandates issued in type 2 diabetes treatment guidelines. The increasing longevity enjoyed by our populace places the onus on clinical care to play the “long game” in using targeted treatments for glucose control in patients with, or at risk for, cognitive decline to maintain cognitive wellness later in life. This article reviews critical emerging data for scientists and trialists and translates new enhancements in patient care for practitioners.
Literature
1.
ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. Older adults: standards of care in diabetes—2023. Diabetes Care. 2023;46(Supplement_1):S216–29.PubMedCrossRef
2.
Alagiakrishnan K, Zhao N, Mereu L, Senior P, Senthilselvan A. Montreal cognitive assessment is superior to standardized mini-mental status exam in detecting mild cognitive impairment in the middle-aged and elderly patients with type 2 diabetes mellitus. Biomed Res Int. 2013;2013:1–5.CrossRef
3.
Yuan X-Y, Wang X-G. Mild cognitive impairment in type 2 diabetes mellitus and related risk factors: a review. Rev Neurosci. 2017;28(7):715–23.PubMedCrossRef
4.
5.
U.S. Centers for Disease Control and Prevention. No Title. National Diabetes Statistics Report. 2024 [Accessed 2024 Jun 25].
6.
Brookmeyer R, Abdalla N, Kawas CH, Corrada MM. Forecasting the prevalence of preclinical and clinical Alzheimer’s disease in the United States. Alzheimer’s Dement. 2018;14(2):121–9.CrossRef
7.
Zhao H, Wu C, Zhang X, Wang L, Sun J, Zhuge F. Insulin resistance is a risk factor for mild cognitive impairment in elderly adults with T2DM. Open Life Sci. 2019;14(1):255–61.PubMedPubMedCentralCrossRef
8.
Isaacson RS, Ganzer CA, Hristov H, Hackett K, Caesar E, Cohen R, et al. The clinical practice of risk reduction for Alzheimer’s disease: a precision medicine approach. Alzheimer’s Dement. 2018;14(12):1663–73.CrossRef
9.
Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome. Circulation. 2005;112(17):2735–52.PubMedCrossRef
10.
Mallorquí-Bagué N, Lozano-Madrid M, Toledo E, Corella D, Salas-Salvadó J, Cuenca-Royo A, et al. Type 2 diabetes and cognitive impairment in an older population with overweight or obesity and metabolic syndrome: baseline cross-sectional analysis of the PREDIMED-plus study. Sci Rep. 2018;8(1):16128.PubMedPubMedCentralCrossRef
11.
Fortea J, Pegueroles J, Alcolea D, Belbin O, Dols-Icardo O, Vaqué-Alcázar L, et al. APOE4 homozygosity represents a distinct genetic form of Alzheimer’s disease. Nat Med. 2024;30(5):1284–91.PubMedCrossRef
12.
Jaarsma E, Nooyens A, Kok AAL, Köhler S, van Boxtel M, Verschuren WMM, et al. Modifiable risk factors for accelerated decline in processing speed: results from three Dutch population cohorts. J Prev Alzheimer’s Dis. 2024;11(1):108–16.
13.
Stanciu S, Rusu E, Miricescu D, Radu AC, Axinia B, Vrabie AM, et al. Links between metabolic syndrome and hypertension: the relationship with the current antidiabetic drugs. Metabolites. 2023;13(1):87.PubMedPubMedCentralCrossRef
14.
Gorska-Ciebiada M, Saryusz-Wolska M, Ciebiada M, Loba J. Mild cognitive impairment and depressive symptoms in elderly patients with diabetes: prevalence, risk factors, and comorbidity. J Diabetes Res. 2014;2014:1–7.CrossRef
15.
Lu Y, Pike JR, Hoogeveen RC, Walker KA, Raffield LM, Selvin E, et al. Liver integrity and the risk of Alzheimer’s disease and related dementias. Alzheimers Dement. 2024;20(3):1913–22.PubMedCrossRef
16.
Targher G, Corey KE, Byrne CD, Roden M. The complex link between NAFLD and type 2 diabetes mellitus — mechanisms and treatments. Nat Rev Gastroenterol Hepatol. 2021;18(9):599–612.PubMedCrossRef
17.
Feinkohl I, Aung PP, Keller M, Robertson CM, Morling JR, McLachlan S, et al. Severe hypoglycemia and cognitive decline in older people with type 2 diabetes: the Edinburgh type 2 diabetes study. Diabetes Care. 2014;37(2):507–15.PubMedCrossRef
18.
Yaffe K. Association between hypoglycemia and dementia in a biracial cohort of older adults with diabetes mellitus. JAMA Intern Med. 2013;173(14):1300.PubMedPubMedCentralCrossRef
19.
Biessels GJ, Strachan MWJ, Visseren FLJ, Kappelle LJ, Whitmer RA. Dementia and cognitive decline in type 2 diabetes and prediabetic stages: towards targeted interventions. Lancet Diabetes Endocrinol. 2014;2(3):246–55.PubMedCrossRef
20.
Chatterjee S, Peters SAE, Woodward M, Mejia Arango S, Batty GD, Beckett N, et al. Type 2 diabetes as a risk factor for dementia in women compared with men: a pooled analysis of 2.3 million people comprising more than 100,000 cases of dementia. Diabetes Care. 2016;39(2):300–7.PubMedCrossRef
21.
Xue M, Xu W, Ou Y-N, Cao X-P, Tan M-S, Tan L, et al. Diabetes mellitus and risks of cognitive impairment and dementia: a systematic review and meta-analysis of 144 prospective studies. Ageing Res Rev. 2019;55:100944.PubMedCrossRef
22.
Thomassen JQ, Tolstrup JS, Benn M, Frikke-Schmidt R. Type-2 diabetes and risk of dementia: observational and Mendelian randomisation studies in 1 million individuals. Epidemiol Psychiatr Sci. 2020;29:e118.PubMedPubMedCentralCrossRef
23.
Srikanth V, Sinclair AJ, Hill-Briggs F, Moran C, Biessels GJ. Type 2 diabetes and cognitive dysfunction—towards effective management of both comorbidities. Lancet Diabetes Endocrinol. 2020;8(6):535–45.PubMedCrossRef
24.
Willmann C, Brockmann K, Wagner R, Kullmann S, Preissl H, Schnauder G, et al. Insulin sensitivity predicts cognitive decline in individuals with prediabetes. BMJ Open Diabetes Res Care. 2020;8(2):e001741.PubMedPubMedCentralCrossRef
25.
Butterfield DA, Di Domenico F, Barone E. Elevated risk of type 2 diabetes for development of Alzheimer disease: a key role for oxidative stress in brain. Biochim Biophys Acta - Mol Basis Dis. 2014;1842(9):1693–706.CrossRef
26.
Barone E, Tramutola A, Triani F, Calcagnini S, Di Domenico F, Ripoli C, et al. Biliverdin reductase-a mediates the beneficial effects of intranasal insulin in alzheimer disease. Mol Neurobiol. 2019;56(4):2922–43.PubMedCrossRef
27.
Dragicevic N, Mamcarz M, Zhu Y, Buzzeo R, Tan J, Arendash GW, et al. Mitochondrial amyloid-β levels are associated with the extent of mitochondrial dysfunction in different brain regions and the degree of cognitive impairment in Alzheimer’s transgenic mice. Zhu X, Beal MF, Wang X, Perry G, Smith MA, editors. J Alzheimer’s Dis. 2010;20(s2):S535–50.CrossRef
28.
29.
Abbatecola AM, Lattanzio F, Molinari AM, Cioffi M, Mansi L, Rambaldi P, et al. Rosiglitazone and cognitive stability in older individuals with type 2 diabetes and mild cognitive impairment. Diabetes Care. 2010;33(8):1706–11.PubMedPubMedCentralCrossRef
30.
31.
Barone E, Di Domenico F, Perluigi M, Butterfield DA. The interplay among oxidative stress, brain insulin resistance and AMPK dysfunction contribute to neurodegeneration in type 2 diabetes and Alzheimer disease. Free Radic Biol Med. 2021;176(859):16–33.PubMedPubMedCentralCrossRef
32.
Barone E, Di Domenico F, Cenini G, Sultana R, Cini C, Preziosi P, et al. Biliverdin reductase-A protein levels and activity in the brains of subjects with Alzheimer disease and mild cognitive impairment. Biochim Biophys Acta - Mol Basis Dis. 2011;1812(4):480–7.CrossRef
33.
de la Monte SM, Tong M, Wands JR. The 20-year voyage aboard the journal of Alzheimer’s disease: docking at ‘type 3 diabetes’, environmental/exposure factors, pathogenic mechanisms, and potential treatments. Perry G, Avila J, Tabaton M, Zhu X, editors. J Alzheimer’s Dis. 2018;62(3):1381–90.CrossRef
34.
Alkasabera A, Onyali CB, Anim-Koranteng C, Shah HE, Ethirajulu A, Bhawnani N, et al. The effect of type-2 diabetes on cognitive status and the role of anti-diabetes medications. Cureus. 2021;13(11):e19176.PubMedPubMedCentral
35.
Yoon JH, Hwang JH, Son SU, Choi J, You SW, Park H, et al. How can insulin resistance cause Alzheimer’s disease? Int J Mol Sci MDPI. 2023;24:3506.CrossRef
36.
Howarth C, Gleeson P, Attwell D. Updated energy budgets for neural computation in the neocortex and cerebellum. J Cereb Blood Flow Metab. 2012;32(7):1222–32.PubMedPubMedCentralCrossRef
37.
38.
Perluigi M, Di Domenico F, Butterfield DA. Oxidative damage in neurodegeneration: roles in the pathogenesis and progression of Alzheimer disease. Physiol Rev. 2024;104(1):103–97.PubMedCrossRef
39.
Tang BL. Glucose, glycolysis, and neurodegenerative diseases. J Cell Physiol. 2020;235(11):7653–62.PubMedCrossRef
40.
Seaquist RE, Tkac I, Damberg G, Thomas W, Gruetter R. Brain glucose concentrations in poorly controlled diabetes mellitus as measured by high-field magnetic resonance spectroscopy. Metabolism. 2005;54(8):1008–13.PubMedCrossRef
41.
Jacob RJ, Fan X, Evans ML, Dziura J, Sherwin RS. Brain glucose levels are elevated in chronically hyperglycemic diabetic rats: No evidence for protective adaptation by the blood brain barrier. Metabolism. 2002;51(12):1522–4.PubMedCrossRef
42.
Holloway GP, Han XX, Jain SS, Bonen A, Chabowski A. Chronic muscle stimulation improves insulin sensitivity while increasing subcellular lipid droplets and reducing selected diacylglycerol and ceramide species in obese Zucker rats. Diabetologia. 2014;57(4):832–40.PubMedCrossRef
43.
Maciejczyk M, Matczuk J, Żendzian-Piotrowska M, Niklińska W, Fejfer K, Szarmach I, et al. Eight-week consumption of high-sucrose diet has a pro-oxidant effect and alters the function of the salivary glands of rats. Nutrients. 2018;10(10):1530.PubMedPubMedCentralCrossRef
44.
Arnold SE, Arvanitakis Z, Macauley-Rambach SL, Koenig AM, Wang HY, Ahima RS, et al. Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums. Nat Rev Neurol. 2018;14:168–81.PubMedPubMedCentralCrossRef
45.
Talbot K, Wang H-Y, Kazi H, Han L-Y, Bakshi KP, Stucky A, et al. Demonstrated brain insulin resistance in Alzheimer’s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest. 2012;122(4):1316–38.PubMedPubMedCentralCrossRef
46.
Pignalosa FC, Desiderio A, Mirra P, Nigro C, Perruolo G, Ulianich L, et al. Diabetes and cognitive impairment: a role for glucotoxicity and dopaminergic dysfunction. Int J Mol Sci. 2021;22(22):12366.PubMedPubMedCentralCrossRef
47.
Prentki M, Peyot M-L, Masiello P, Madiraju SRM. Nutrient-induced metabolic stress, adaptation, detoxification, and toxicity in the pancreatic β-cell. Diabetes. 2020;69(3):279–90.PubMedCrossRef
48.
Rachfal AW, Grant SF, Schwartz SS. The diabetes syndrome – a collection of conditions with common, interrelated pathophysiologic mechanisms. Int J Gen Med. 2021;14:923–36.PubMedPubMedCentralCrossRef
49.
Banks WA. The blood-brain barrier interface in diabetes mellitus: dysfunctions, mechanisms and approaches to treatment. Curr Pharm Des. 2020;26(13):1438–47.PubMedCrossRef
50.
Yan L-J. Pathogenesis of chronic hyperglycemia: from reductive stress to oxidative stress. J Diabetes Res. 2014;2014:1–11.
51.
Ruegsegger GN, Vanderboom PM, Dasari S, Klaus KA, Kabiraj P, McCarthy CB, et al. Exercise and metformin counteract altered mitochondrial function in the insulin-resistant brain. JCI Insight. 2019;4(18):e130681.
52.
De Felice FG, Lourenco MV, Ferreira ST. How does brain insulin resistance develop in Alzheimer’s disease? Alzheimer’s Dement. 2014;10(1 Suppl):S26–32.
53.
Perluigi M, Barone E, Di Domenico F, Butterfield DA. Aberrant protein phosphorylation in Alzheimer disease brain disturbs pro-survival and cell death pathways. Biochim Biophys Acta - Mol Basis Dis. 2016;1862(10):1871–82.CrossRef
54.
Singh DD, Shati AA, Alfaifi MY, Elbehairi SEI, Han I, Choi E-H, et al. Development of dementia in type 2 diabetes patients: mechanisms of insulin resistance and antidiabetic drug development. Cells. 2022;11(23):3767.PubMedPubMedCentralCrossRef
55.
Arvanitakis Z, Capuano AW, Wang H-Y, Schneider JA, Kapasi A, Bennett DA, et al. Brain insulin signaling and cerebrovascular disease in human postmortem brain. Acta Neuropathol Commun. 2021;9(1):71.PubMedPubMedCentralCrossRef
56.
Zheng M, Wang P. Role of insulin receptor substance-1 modulating PI3K/Akt insulin signaling pathway in Alzheimer’s disease. 3 Biotech. 2021;11(4):179.PubMedPubMedCentralCrossRef
57.
Tramutola A, Triplett JC, Di Domenico F, Niedowicz DM, Murphy MP, Coccia R, et al. Alteration of mTOR signaling occurs early in the progression of Alzheimer disease (AD): analysis of brain from subjects with pre-clinical AD, amnestic mild cognitive impairment and late-stage AD. J Neurochem. 2015;133(5):739–49.PubMedCrossRef
58.
Butterfield DA, Boyd-Kimball D. Redox proteomics and amyloid β-peptide: insights into Alzheimer disease. J Neurochem. 2019;151(4):459–87.PubMedCrossRef
59.
Lu Y, Jiang X, Liu S, Li M. Changes in cerebrospinal fluid tau and β-amyloid levels in diabetic and prediabetic patients: a meta-analysis. Front Aging Neurosci. 2018:10:271.
60.
Xiong H, Zheng C, Wang J, Song J, Zhao G, Shen H, et al. The neuroprotection of liraglutide on Alzheimer-like learning and memory impairment by modulating the hyperphosphorylation of tau and neurofilament proteins and insulin signaling pathways in mice. Alonso A, Gong C, editors. J Alzheimer’s Dis. 2013;37(3):623–35.CrossRef
61.
Cho SB. Comorbidity genes of Alzheimer’s disease and type 2 diabetes associated with memory and cognitive function. Int J Mol Sci. 2024;25(4):2211.
62.
Lemche E, Killick R, Mitchell J, Caton PW, Choudhary P, Howard JK. Molecular mechanisms linking type 2 diabetes mellitus and late-onset Alzheimer’s disease: a systematic review and qualitative meta-analysis. Neurobiol Dis. 2024;196:106485.PubMedCrossRef
63.
Sarnowski C, Huan T, Ma Y, Joehanes R, Beiser A, DeCarli CS, et al. Multi-tissue epigenetic analysis identifies distinct associations underlying insulin resistance and Alzheimer’s disease at CPT1A locus. Clin Epigenetics. 2023;15(1):173.PubMedPubMedCentralCrossRef
64.
Schwartz SS, Epstein S, Corkey BE, Grant SFA, Gavin JR III, Aguilar RB, et al. A unified pathophysiological construct of diabetes and its complications. Trends Endocrinol Metab. 2017;28(9):645–55.PubMedCrossRef
65.
Borson S, Scanlan JM, Chen P, Ganguli M. The Mini-Cog as a Screen for dementia: validation in a population-based sample. J Am Geriatr Soc. 2003;51(10):1451–4.PubMedCrossRef
66.
Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695–9.PubMedCrossRef
67.
Cruz-Oliver DM, Malmstrom TK, Roegner M, Tumosa N, Grossberg GT. Cognitive deficit reversal as shown by changes in the Veterans Affairs Saint Louis University Mental Status (SLUMS) examination scores 7.5 years later. J Am Med Dir Assoc. 2014;15(9):687.e5–687.e10.PubMedCrossRef
68.
Tsoy E, Sideman AB, Piña Escudero SD, Pintado-Caipa M, Kanjanapong S, Al-Rousan T, et al. Global perspectives on brief cognitive assessments for dementia diagnosis. J Alzheimer’s Dis. 2021;82(3):1001–13.CrossRef
69.
Weintraub S. Neuropsychological assessment in dementia diagnosis. Contin Lifelong Learn Neurol. 2022;28(3):781–99.CrossRef
70.
Reisberg B, Doody R, Stöffler A, Schmitt F, Ferris S, Möbius HJ. Memantine in moderate-to-severe Alzheimer’s disease. N Engl J Med. 2003;348(14):1333–41.PubMedCrossRef
71.
Bukhbinder AS, Ling Y, Hasan O, Jiang X, Kim Y, Phelps KN, et al. Risk of Alzheimer’s disease following influenza vaccination: a claims-based cohort study using propensity score matching. Kostev K, editor. J Alzheimer’s Dis. 2022;88(3):1061–74.CrossRef
72.
Schnier C, Janbek J, Lathe R, Haas J. Reduced dementia incidence after varicella zoster vaccination in Wales 2013–2020. Alzheimer’s Dement Transl Res Clin Interv. 2022;8(1):e12293.
73.
Mullard A. FDA approves third anti-amyloid antibody for Alzheimer disease. Nat Rev Drug Discov. 2024;23(8):571.
74.
Wium-Andersen IK, Osler M, Jørgensen MB, Rungby J, Wium-Andersen MK. Antidiabetic medication and risk of dementia in patients with type 2 diabetes: a nested case-control study. Eur J Endocrinol. 2019;181(5):499–507.PubMedCrossRef
75.
Tian S, Jiang J, Wang J, Zhang Z, Miao Y, Ji X, et al. Comparison on cognitive outcomes of antidiabetic agents for type 2 diabetes: a systematic review and network meta-analysis. Diabetes Metab Res Rev. 2023;39(7):e3673.PubMedCrossRef
76.
77.
Weinstein G, Davis-Plourde KL, Conner S, Himali JJ, Beiser AS, Lee A, et al. Association of metformin, sulfonylurea and insulin use with brain structure and function and risk of dementia and Alzheimer’s disease: pooled analysis from 5 cohorts. Bayer A, editor. PLoS One. 2019;14(2):e0212293.PubMedPubMedCentralCrossRef
78.
Biessels GJ, Verhagen C, Janssen J, van den Berg E, Wallenstein G, Zinman B, et al. Effects of linagliptin vs glimepiride on cognitive performance in type 2 diabetes: results of the randomised double-blind, active-controlled CAROLINA-COGNITION study. Diabetologia. 2021;64(6):1235–45.PubMedPubMedCentralCrossRef
79.
Cukierman-Yaffe T, Gerstein HC, Colhoun HM, Diaz R, García-Pérez L-E, Lakshmanan M, et al. Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial. Lancet Neurol. 2020;19(7):582–90.PubMedCrossRef
80.
Shin A, Koo BK, Lee JY, Kang EH. Risk of dementia after initiation of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in adults aged 40–69 years with type 2 diabetes: population based cohort study. BMJ. 2024;28:e079475.CrossRef
81.
Šimonienė D, Veličkienė D. Relation between exogenous insulin and cognitive function in type 2 diabetes mellitus. Medicina (B Aires). 2021;57(9):943.CrossRef
82.
83.
Lin C-H, Sheu WH-H. Hypoglycaemic episodes and risk of dementia in diabetes mellitus: 7-year follow-up study. J Intern Med. 2013;273(1):102–10.PubMedCrossRef
84.
de Galan BE, Zoungas S, Chalmers J, Anderson C, Dufouil C, Pillai A, et al. Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial. Diabetologia. 2009;52(11):2328–36.PubMedCrossRef
85.
Fanelli CG, Porcellati F, Pampanelli S, Bolli GB. Insulin therapy and hypoglycaemia: the size of the problem. Diabetes Metab Res Rev. 2004;20(S2):S32–42.PubMedCrossRef
86.
Nilsson M, Jensen N, Gejl M, Bergmann ML, Storgaard H, Zander M, et al. Experimental non-severe hypoglycaemia substantially impairs cognitive function in type 2 diabetes: a randomised crossover trial. Diabetologia. 2019;62(10):1948–58.PubMedCrossRef
87.
Dunkley AJ, Fitzpatrick C, Gray LJ, Waheed G, Heller SR, Frier BM, et al. Incidence and severity of hypoglycaemia in type 2 diabetes by treatment regimen: a UK multisite 12-month prospective observational study. Diabetes, Obes Metab. 2019;21(7):1585–95.PubMedCrossRef
88.
Gorst C, Kwok CS, Aslam S, Buchan I, Kontopantelis E, Myint PK, et al. Long-term glycemic variability and risk of adverse outcomes: a systematic review and meta-analysis. Diabetes Care. 2015;38(12):2354–69.PubMedCrossRef
89.
Song J, Bai H, Xu H, Xing Y, Chen S. HbA1c variability and the risk of dementia in patients with diabetes: a meta-analysis. Seixas A, editor. Int J Clin Pract. 2022;2022:1–10.
90.
Lin B, Koibuchi N, Hasegawa Y, Sueta D, Toyama K, Uekawa K, et al. Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice. Cardiovasc Diabetol. 2014;13(1):148.PubMedPubMedCentralCrossRef
91.
Sa-nguanmoo P, Tanajak P, Kerdphoo S, Jaiwongkam T, Pratchayasakul W, Chattipakorn N, et al. SGLT2-inhibitor and DPP-4 inhibitor improve brain function via attenuating mitochondrial dysfunction, insulin resistance, inflammation, and apoptosis in HFD-induced obese rats. Toxicol Appl Pharmacol. 2017;333:43–50.PubMedCrossRef
92.
Sattar N, Lee MMY, Kristensen SL, Branch KRH, Del Prato S, Khurmi NS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021;9(10):653–62.PubMedCrossRef
93.
Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–306.PubMedCrossRef
94.
Pratley RE, Cannon CP, Cherney DZI, Cosentino F, McGuire DK, Essex MN, et al. Cardiorenal outcomes, kidney function, and other safety outcomes with ertugliflozin in older adults with type 2 diabetes (VERTIS CV): secondary analyses from a randomised, double-blind trial. Lancet Heal Longev. 2023;4(4):e143–54.CrossRef
95.
Packer M. Critical reanalysis of the mechanisms underlying the cardiorenal benefits of SGLT2 inhibitors and reaffirmation of the nutrient deprivation signaling/autophagy hypothesis. Circulation. 2022;146:1383–405.PubMedPubMedCentralCrossRef
96.
Shaikh S, Rizvi SMD, Shakil S, Riyaz S, Biswas D, Jahan R. Forxiga (dapagliflozin): plausible role in the treatment of diabetes-associated neurological disorders. Biotechnol Appl Biochem. 2016;63(1):145–50.PubMedCrossRef
97.
Kosaraju J, Gali CC, Khatwal RB, Dubala A, Chinni S, Holsinger RMD, et al. Saxagliptin: a dipeptidyl peptidase-4 inhibitor ameliorates streptozotocin induced Alzheimer’s disease. Neuropharmacology. 2013;72:291–300.PubMedCrossRef
98.
McClean PL, Hölscher C. Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer’s disease. Neuropharmacology. 2014;76:57–67.PubMedCrossRef
99.
Chen S, Liu A, An F, Yao W, Gao X. Amelioration of neurodegenerative changes in cellular and rat models of diabetes-related Alzheimer’s disease by exendin-4. Age (Omaha). 2012;34(5):1211–24.CrossRef
100.
Esterline R, Oscarsson J, Burns J. A role for sodium glucose cotransporter 2 inhibitors (SGLT2is) in the treatment of Alzheimer’s disease? In 2020. p. 113–40.
101.
Seaquist ER, Anderson J, Childs B, Cryer P, Dagogo-Jack S, Fish L, et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and The Endocrine Society. Diabetes Care. 2013;36(5):1384–95.PubMedPubMedCentralCrossRef
102.
Palmer SC, Tendal B, Mustafa RA, Vandvik PO, Li S, Hao Q, et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ. 2021;13:372:m4573.
103.
Blanco CA, Garcia K, Singson A, Smith WR. Use of SGLT2 inhibitors reduces heart failure and hospitalization: a multicenter, real-world evidence study. Perm J. 2023;27(1):77–87.PubMedPubMedCentralCrossRef
104.
Claxton A, Baker LD, Hanson A, Trittschuh EH, Cholerton B, Morgan A, et al. Long-acting intranasal insulin detemir improves cognition for adults with mild cognitive impairment or early-stage Alzheimer’s disease dementia. J Alzheimer’s Dis. 2015;45(4):1269–70.CrossRef
105.
Reger MA, Watson GS, Green PS, Baker LD, Cholerton B, Fishel MA, et al. Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-β in memory-impaired older adults. J Alzheimer’s Dis. 2008;13(3):323–31.CrossRef
106.
Reger MA, Watson GS, Frey WH, Baker LD, Cholerton B, Keeling ML, et al. Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype. Neurobiol Aging. 2006;27(3):451–8.PubMedCrossRef
107.
Craft S, Raman R, Chow TW, Rafii MS, Sun C-K, Rissman RA, et al. Safety, efficacy, and feasibility of intranasal insulin for the treatment of mild cognitive impairment and Alzheimer disease dementia. JAMA Neurol. 2020;77(9):1099.PubMedCrossRef
108.
Craft S. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment. Arch Neurol. 2012;69(1):29.PubMedCrossRef
109.
Koychev I, Adler AI, Edison P, Tom B, Milton JE, Butchart J, et al. Protocol for a double-blind placebo-controlled randomised controlled trial assessing the impact of oral semaglutide in amyloid positivity (ISAP) in community dwelling UK adults. BMJ Open. 2024;14(6):e081401.PubMedPubMedCentralCrossRef
110.
Davidy T, Yore I, Cukierman-Yaffe T, Ravona-Springer R, Livny A, Lesman-Segev OH, et al. A feasibility study of the combination of intranasal insulin with oral semaglutide for cognition in older adults with metabolic syndrome at high dementia risk- Study rationale and design. Mech Ageing Dev. 2024;218:111898.PubMedCrossRef
111.
Sinclair SH, Miller E, Talekar KS, Schwartz SS. Diabetes mellitus associated neurovascular lesions in the retina and brain: a review. Front Ophthalmol. 2022;2:1012804.
112.
Bubber P, Haroutunian V, Fisch G, Blass JP, Gibson GE. Mitochondrial abnormalities in Alzheimer brain: mechanistic implications. Ann Neurol. 2005;57(5):695–703.PubMedCrossRef
Metadata
Title
The double life of glucose metabolism: brain health, glycemic homeostasis, and your patients with type 2 diabetes
Authors
Stanley S. Schwartz
Mary E. Herman
May Thet Hmu Tun
Eugenio Barone
D. Allan Butterfield
Publication date
18-12-2024
Publisher
BioMed Central
Published in
BMC Medicine / Issue 1/2024
Electronic ISSN: 1741-7015
DOI
https://doi.org/10.1186/s12916-024-03763-8

Other articles of this Issue 1/2024

Has multimorbidity and frailty in adult hospital admissions changed over the last 15 years? A retrospective study of 107 million admissions in England

  • Open Access
  • Original Research

Consistency, completeness and external validity of ethnicity recording in NHS primary care records: a cohort study in 25 million patients’ records at source using OpenSAFELY

  • Open Access
  • Original Research

Between faces: childhood adversity is associated with reduced threat-safety discrimination during facial expression processing in adolescence

Telomere length in relation to fecundability and use of assisted reproductive technologies: the Norwegian Mother, Father, and Child Cohort Study

How does surgery influence female sexuality in patients with endometriosis compared to those with other benign gynecological conditions?

Association between inflammatory bowel disease and cancer risk: evidence triangulation from genetic correlation, Mendelian randomization, and colocalization analyses across East Asian and European populations

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Read more
Image Credits